

Laura R. Craft, MPH President and Director of Healthcare Analytics

Direct: (510) 463-0133 lcraft@onpointanalytics.com

Phone: (510) 463-0130

Fax: (510) 463-0131

President, 2004-Present:

Laura Craft is a co-founder and the President of OnPoint Analytics, Inc., an economic, financial and statistical consulting firm. Ms. Craft holds a Master of Public Health degree from the University of California, Berkeley as well as a J.D. Her specializations include healthcare finance, hospital system and other healthcare business structures, private and governmental healthcare programs, insurance claims and reimbursement procedures, drug development and marketing, drug distribution and payment mechanisms, and the role played by key industry participants such as Pharmacy Benefit Managers. Her opinions cover mechanisms affecting price determination and demand for prescription drugs including formulary structures, rebate negotiations, and PBM contracting with pharmacies and insurers/payors. She frequently testifies on claims adjudication processes and legal requirements resulting in the creation and preservation of claims data.

Ms. Craft has worked on over 65 pharmaceutical cases encompassing virtually every therapeutic class of medications. Many of these have involved the certification of Classes based on alleged antitrust violations or marketing of adulterated products. Ms. Craft has also testified on the demand for residential services to treat substance abuse disorders, intercompany relationships among vertically integrated healthcare providers, and lost profits from business interruption. In addition to providing expert testimony, Ms. Craft consults on pre-filing evaluations, discovery, and settlements.

PUBLICATIONS

Empirical Challenges in Pharma Litigation, Craft, Kovach, Wallace and Cortez (2017)

TEACHING

Instructor for Continuing Legal Education programs certified in major jurisdictions throughout the U.S. involving:

- Emerging antitrust issues in pharmaceuticals and life sciences sectors
- Data and empirical issues in pharmaceutical litigation
- Antitrust claims involving pharmaceutical products
- Estimation of intellectual property damages

EDUCATION

University of California, Berkeley Master of Public Health

University of California, Hastings College of the Law *Juris Doctor (J.D.)*

University of California, Los Angeles Bachelor of Arts (B.A.)

EXPERT TESTIMONY

GEHA v. Actelion Pharmaceuticals (Tracleer)
Cohen Milstein Sellers & Toll PLLC (2022–)

• Expert Report, Deposition Testimony

In re: Actos End-Payor Antitrust Litigation Cohen Milstein Sellers & Toll PLLC (2023–)

• Expert Reports, Deposition and Hearing Testimony

In re: Generic Pharmaceuticals Pricing Litigation (Clobetasol, Clomipramine HCL) Fine, Kaplan and Black, R.P.C. (2022–)

• Expert Reports, Deposition Testimony

In the Matter of the Woolsey Fire Damage to Biozyme Inc. The Bernheim Law Firm (2024–)

• Expert Report

In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation Cohen Milstein Sellers & Toll PLLC (2023–)

• Expert Reports, Deposition Testimony

MSP Recovery Claims, Series LLC, et al. v. Express Scripts, Inc., et al. (Acthar) Milberg Law Firm (2023)

• Expert Reports, Deposition Testimony

United States of America ex rel. Sarah Behnke v. CVS Caremark Corporation, et al. Berger Montague (2022–)

• Expert Reports, Deposition Testimony

In re: Lipitor Antitrust Litigation
Cohen Milstein Sellers & Toll PLLC (2023)

• Expert Reports, Deposition Testimonies, Hearing Testimony

In re: Xyrem (Sodium Oxybate) Antitrust Litigation Girard Sharp (2022–)

• Expert Report, Deposition Testimony

In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation Kanner & Whiteley, L.L.C. and Golomb & Honik, P.C. (2021–)

• Expert Declarations, Deposition Testimonies

Woolsey Fire Damage to Malibu Hill and Prominence Treatment Center Facilities The Bernheim Law Firm (2022)

Expert Report

Zydus Worldwide DMCC v. Teva API Inc. (rotigotine) Locke Lord (2022–)

• Expert Report, Deposition Testimony

Peter Staley, et al. v. Gilead Sciences, Inc., et al. Hilliard & Shadowen, LLP (2021–)

• Expert Report, Deposition Testimony

In re: Novartis and Par Antitrust Litigation (Exforge)
Labaton Sucharow LLP (2021–)

• Expert Declaration, Deposition Testimony

In re: Ranbaxy Generic Drug Application Antitrust Litigation Lowey Dannenberg, P.C. (2020–)

• Expert Reports, Deposition Testimony

In re: Namenda Indirect Purchaser Antitrust Litigation Miller Law LLC (2020–)

• Expert Declarations, Deposition Testimony

In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation Zwerling, Schachter & Zwerling, LLP (2019–)

• Expert Declarations, Deposition Testimony, Hearing Testimony

In re: Zetia (Ezetimibe) Antitrust Litigation Miller Law LLC (2019–)

• Expert Declarations, Deposition Testimony, Hearing Testimony

In re: Niaspan Antitrust Litigation Wexler Wallace, LLP (2018-)

• Expert Declarations, Deposition Testimony

In re: Loestrin Antitrust Litigation Cohen Milstein Sellers & Toll (2018–)

• Expert Declarations, Deposition Testimony, Hearing Testimony